- Home
- EPIX vs ACET Comparison
EPIX vs ACET Comparison
Compare EPIX & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- ACET
- Stock Information
- Founded
- EPIX 2009
- ACET 1947
- Country
- EPIX Canada
- ACET United States
- Employees
- EPIX N/A
- ACET N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- EPIX Health Care
- ACET Health Care
- Exchange
- EPIX Nasdaq
- ACET Nasdaq
- Market Cap
- EPIX 75.9M
- ACET 63.8M
- IPO Year
- EPIX N/A
- ACET N/A
- Fundamental
- Price
- EPIX $1.87
- ACET $0.75
- Analyst Decision
- EPIX Hold
- ACET Strong Buy
- Analyst Count
- EPIX 3
- ACET 7
- Target Price
- EPIX $2.00
- ACET $5.60
- AVG Volume (30 Days)
- EPIX 452.3K
- ACET 386.5K
- Earning Date
- EPIX 08-04-2025
- ACET 08-12-2025
- Dividend Yield
- EPIX N/A
- ACET N/A
- EPS Growth
- EPIX N/A
- ACET N/A
- EPS
- EPIX N/A
- ACET N/A
- Revenue
- EPIX N/A
- ACET N/A
- Revenue This Year
- EPIX N/A
- ACET N/A
- Revenue Next Year
- EPIX N/A
- ACET N/A
- P/E Ratio
- EPIX N/A
- ACET N/A
- Revenue Growth
- EPIX N/A
- ACET N/A
- 52 Week Low
- EPIX $1.40
- ACET $0.45
- 52 Week High
- EPIX $7.88
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- EPIX 63.77
- ACET 53.15
- Support Level
- EPIX $1.86
- ACET $0.75
- Resistance Level
- EPIX $1.88
- ACET $0.82
- Average True Range (ATR)
- EPIX 0.02
- ACET 0.05
- MACD
- EPIX 0.00
- ACET 0.00
- Stochastic Oscillator
- EPIX 94.74
- ACET 50.51
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.